Unadjusted and adjusted hazard ratios and 95% CIs for the association between baseline characteristics and discontinuation of TDF from TDF-containing ART regimens in participants in the PEARLS, OCTANE, STRIDE, and REMEMBER clinical trials.

Luc Heerkens (16954658)
Laurens A. van Kleef (16954661)
Robert J. de Knegt (11930912)
Trudy Voortman (3497534)
Johanna M. Geleijnse (7246343)

September 2023

Associations in hazard ratios of FLI as continuous exposure in relation to CVD mortality (A) and all...

Risk for treatment discontinuation in treatment-naive patients (Treatment effects showing Hazard Ratios from univariate and multivariate Cox regression models).

Amanda Häggblom (393667)
Stefan Lindbäck (3753223)
Magnus Gisslén (176506)
Leo Flamholc (3753220)
Bo Hejdeman (599663)
Andreas Palmborg (3753214)
Amy Leval (350406)
Eva Herweijer (776415)
Sverrir Valgardsson (3753217)
Veronica Svedhem (2838425)

February 2017

Risk for treatment discontinuation in treatment-naive patients (Treatment effects showing Hazard ...

Unadjusted and adjusted hazard ratios (HR) according to CD4 count at start of ART and at 10 years after start of ART.

Adam Trickey (2950596)
Margaret T. May (627545)
Janne Vehreschild (2950620)
Niels Obel (135891)
Michael John Gill (2950599)
Heidi Crane (2950614)
Christoph Boesecke (779781)
Hasina Samji (486303)
Sophie Grabar (697347)
Charles Cazanave (606308)
Matthias Cavassini (146654)
Leah Shepherd (2950608)
Antonella d’Arminio Monforte (2198545)
Colette Smit (89579)
Michael Saag (170633)
Fiona Lampe (282424)
Vicky Hernando (2950605)
Marta Montero (2950611)
Robert Zangerle (288358)
Amy C. Justice (229955)
Timothy Sterling (2950602)
Jose Miro (2950623)
Suzanne Ingle (2950617)
Jonathan A. C. Sterne (123321)

August 2016

Unadjusted and adjusted hazard ratios (HR) according to CD4 count at start of ART and at 10 years...

Baseline characteristics of participants who started TDF-containing ART regimens in the PEARLS, OCTANE, STRIDE, AND REMEMBER clinical trials.

McNeil Ngongondo (17735829)
Justin Ritz (437660)
Michael D. Hughes (7251230)
Mitch Matoga (17735832)
Mina C. Hosseinipour (8292558)

January 2024

Baseline characteristics of participants who started TDF-containing ART regimens in the PEARLS, OCTA...

Clinical and Biological characteristics of the 81 patients at baseline, according to TDF exposure.

Hélène Peyriere (827181)
Amandine Cournil (262971)
Marie-Laure Casanova (827182)
Stéphanie Badiou (177316)
Jean-Paul Cristol (177338)
Jacques Reynes (81332)

November 2015

*comparison between the three groups / comparison TDF discontinuation group versus TDF continuati...

Hazard ratios (HR) and 95% Confidence Interval (CI) for progression-free survival (PFS) for studies included in the indirect treatment comparison for cabazitaxel, abiraterone acetate and enzalutamide.

Jon P. Fryzek (5089454)
Heidi Reichert (5089463)
Nicholas Summers (4102141)
Lindsay Townes (5089460)
Robert Deuson (5089451)
Dominik D. Alexander (704966)
Jackie Vanderpuye-Orgle (5089457)

April 2018

Hazard ratios (HR) and 95% Confidence Interval (CI) for progression-free survival (PFS) for studi...

Levels of eGFR and uPCR at baseline, at the time of discontinuation and at the end of follow-up by TDF exposure.

Hélène Peyriere (827181)
Amandine Cournil (262971)
Marie-Laure Casanova (827182)
Stéphanie Badiou (177316)
Jean-Paul Cristol (177338)
Jacques Reynes (81332)

November 2015

Levels of eGFR and uPCR at baseline, at the time of discontinuation and at the end of follow-up b...

Distribution of risk factors and TRD rate in all CCRT arms.

Jing Zhao (21160)
Yingfeng Xia (2833667)
Joseph Kaminski (49955)
Zhonglin Hao (1623361)
Frank Mott (2833670)
Jeff Campbell (2833664)
Ramses Sadek (2833661)
Feng-Ming (Spring) Kong (2833658)

June 2016

(A) TRD rates among trials with different study periods. (B) TRD rates between arms with high and...

Logistic Regression Analysis for All Drug Resistance Factors in the ART-experienced Group.

Fengdi Zhang (3739948)
Li Liu (75607)
Meiyan Sun (679548)
Jianjun Sun (54027)
Hongzhou Lu (198400)

February 2017

Few participants used TDF and few participants had ≤12M between ART to DR testing, so these were ...

Predictors of Discontinuation of Tumor Necrosis Factor Alpha Antagonists.

Anat Fisher (618829)
Ken Bassett (372058)
James M. Wright (372059)
M. Alan Brookhart (459340)
Hugh Freeman (618830)
Colin R. Dormuth (372054)

August 2014

Hazard ratios are presented only for factors that are significant predictors of persistence (p-va...

Network meta-analysis estimates of discontinuation rates due to adverse events for substance classes compared with placebo.

Ramona Meister (3169764)
Alessa von Wolff (834209)
Hannes Mohr (3169767)
Martin Härter (374186)
Yvonne Nestoriuc (293302)
Lars Hölzel (3169770)
Levente Kriston (2157118)

May 2016

Odds ratios higher than 1 reflect a higher discontinuation rate due to adverse events in the subs...

Forest plot of risk ratios (with 95% confidence intervals) of discontinuation for adverse effects for higher doses versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in patients with heart failure with reduced ejection fraction.

Ricky D. Turgeon (6411179)
Michael R. Kolber (428008)
Peter Loewen (6411182)
Ursula Ellis (6411185)
James P. McCormack (367435)

February 2019

Forest plot of risk ratios (with 95% confidence intervals) of discontinuation for adverse effects fo...

Forest plot showing the associations of the time to progression (TTP) between TACE alone group and sorafenib combined with TACE group for patients with unresctable HCC.

Lei Liu (5074)
Hui Chen (28597)
Mengmeng Wang (540017)
Yan Zhao (58882)
Guohong Cai (490597)
Xingshun Qi (448086)
Guohong Han (448089)

March 2014

The result of meta-analysis for TTP between TACE alone group and sorafenib combined with TACE gro...

Efficacy,—Indirect treatment comparison—E/C/F/TDF vs. ABC/3TC + DTG.

Josep M. Llibre (199625)
François Raffi (4923)
Graeme Moyle (2795332)
Georg Behrens (128738)
Stephane Bouee (2795335)
Geraldine Reilly (2795326)
Peter Borg (2795329)
David Piontkowsky (2795320)
Felipe Rogatto (2795323)

May 2016

To the right of zero favors ABC/3TC/DTG (If the risk difference percentage is higher (lower) than...

Hazard ratios (HRs) with their 95% confidence intervals (CIs) of incident knee osteoarthritis between categories of various factors.

Sanna Konstari (6503792)
Laura Sares-Jäske (6503795)
Markku Heliövaara (81299)
Harri Rissanen (4249534)
Paul Knekt (277011)
Jari Arokoski (5576240)
Jouko Sundvall (392546)
Jaro Karppinen (81295)

March 2019

Hazard ratios (HRs) with their 95% confidence intervals (CIs) of incident knee osteoarthritis betwee...

Fig 1 -

Luc Heerkens (16954658)
Laurens A. van Kleef (16954661)
Robert J. de Knegt (11930912)
Trudy Voortman (3497534)
Johanna M. Geleijnse (7246343)

September 2023

Associations in hazard ratios of FLI as continuous exposure in relation to CVD mortality (A) and all...

Risk for treatment discontinuation in treatment-naive patients (Treatment effects showing Hazard Ratios from univariate and multivariate Cox regression models).

Amanda Häggblom (393667)
Stefan Lindbäck (3753223)
Magnus Gisslén (176506)
Leo Flamholc (3753220)
Bo Hejdeman (599663)
Andreas Palmborg (3753214)
Amy Leval (350406)
Eva Herweijer (776415)
Sverrir Valgardsson (3753217)
Veronica Svedhem (2838425)

February 2017

Risk for treatment discontinuation in treatment-naive patients (Treatment effects showing Hazard ...

Unadjusted and adjusted hazard ratios (HR) according to CD4 count at start of ART and at 10 years after start of ART.

Adam Trickey (2950596)
Margaret T. May (627545)
Janne Vehreschild (2950620)
Niels Obel (135891)
Michael John Gill (2950599)
Heidi Crane (2950614)
Christoph Boesecke (779781)
Hasina Samji (486303)
Sophie Grabar (697347)
Charles Cazanave (606308)
Matthias Cavassini (146654)
Leah Shepherd (2950608)
Antonella d’Arminio Monforte (2198545)
Colette Smit (89579)
Michael Saag (170633)
Fiona Lampe (282424)
Vicky Hernando (2950605)
Marta Montero (2950611)
Robert Zangerle (288358)
Amy C. Justice (229955)
Timothy Sterling (2950602)
Jose Miro (2950623)
Suzanne Ingle (2950617)
Jonathan A. C. Sterne (123321)

August 2016

Unadjusted and adjusted hazard ratios (HR) according to CD4 count at start of ART and at 10 years...

Baseline characteristics of participants who started TDF-containing ART regimens in the PEARLS, OCTANE, STRIDE, AND REMEMBER clinical trials.

McNeil Ngongondo (17735829)
Justin Ritz (437660)
Michael D. Hughes (7251230)
Mitch Matoga (17735832)
Mina C. Hosseinipour (8292558)

January 2024

Baseline characteristics of participants who started TDF-containing ART regimens in the PEARLS, OCTA...

Clinical and Biological characteristics of the 81 patients at baseline, according to TDF exposure.

Hélène Peyriere (827181)
Amandine Cournil (262971)
Marie-Laure Casanova (827182)
Stéphanie Badiou (177316)
Jean-Paul Cristol (177338)
Jacques Reynes (81332)

November 2015

*comparison between the three groups / comparison TDF discontinuation group versus TDF continuati...

Hazard ratios (HR) and 95% Confidence Interval (CI) for progression-free survival (PFS) for studies included in the indirect treatment comparison for cabazitaxel, abiraterone acetate and enzalutamide.

Jon P. Fryzek (5089454)
Heidi Reichert (5089463)
Nicholas Summers (4102141)
Lindsay Townes (5089460)
Robert Deuson (5089451)
Dominik D. Alexander (704966)
Jackie Vanderpuye-Orgle (5089457)

April 2018

Hazard ratios (HR) and 95% Confidence Interval (CI) for progression-free survival (PFS) for studi...

Levels of eGFR and uPCR at baseline, at the time of discontinuation and at the end of follow-up by TDF exposure.

Hélène Peyriere (827181)
Amandine Cournil (262971)
Marie-Laure Casanova (827182)
Stéphanie Badiou (177316)
Jean-Paul Cristol (177338)
Jacques Reynes (81332)

November 2015

Levels of eGFR and uPCR at baseline, at the time of discontinuation and at the end of follow-up b...

Distribution of risk factors and TRD rate in all CCRT arms.

Jing Zhao (21160)
Yingfeng Xia (2833667)
Joseph Kaminski (49955)
Zhonglin Hao (1623361)
Frank Mott (2833670)
Jeff Campbell (2833664)
Ramses Sadek (2833661)
Feng-Ming (Spring) Kong (2833658)

June 2016

(A) TRD rates among trials with different study periods. (B) TRD rates between arms with high and...

Logistic Regression Analysis for All Drug Resistance Factors in the ART-experienced Group.

Fengdi Zhang (3739948)
Li Liu (75607)
Meiyan Sun (679548)
Jianjun Sun (54027)
Hongzhou Lu (198400)

February 2017

Few participants used TDF and few participants had ≤12M between ART to DR testing, so these were ...

Predictors of Discontinuation of Tumor Necrosis Factor Alpha Antagonists.

Anat Fisher (618829)
Ken Bassett (372058)
James M. Wright (372059)
M. Alan Brookhart (459340)
Hugh Freeman (618830)
Colin R. Dormuth (372054)

August 2014

Hazard ratios are presented only for factors that are significant predictors of persistence (p-va...

Network meta-analysis estimates of discontinuation rates due to adverse events for substance classes compared with placebo.

Ramona Meister (3169764)
Alessa von Wolff (834209)
Hannes Mohr (3169767)
Martin Härter (374186)
Yvonne Nestoriuc (293302)
Lars Hölzel (3169770)
Levente Kriston (2157118)

May 2016

Odds ratios higher than 1 reflect a higher discontinuation rate due to adverse events in the subs...

Forest plot of risk ratios (with 95% confidence intervals) of discontinuation for adverse effects for higher doses versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in patients with heart failure with reduced ejection fraction.

Ricky D. Turgeon (6411179)
Michael R. Kolber (428008)
Peter Loewen (6411182)
Ursula Ellis (6411185)
James P. McCormack (367435)

February 2019

Forest plot of risk ratios (with 95% confidence intervals) of discontinuation for adverse effects fo...

Forest plot showing the associations of the time to progression (TTP) between TACE alone group and sorafenib combined with TACE group for patients with unresctable HCC.

Lei Liu (5074)
Hui Chen (28597)
Mengmeng Wang (540017)
Yan Zhao (58882)
Guohong Cai (490597)
Xingshun Qi (448086)
Guohong Han (448089)

March 2014

The result of meta-analysis for TTP between TACE alone group and sorafenib combined with TACE gro...

Efficacy,—Indirect treatment comparison—E/C/F/TDF vs. ABC/3TC + DTG.

Josep M. Llibre (199625)
François Raffi (4923)
Graeme Moyle (2795332)
Georg Behrens (128738)
Stephane Bouee (2795335)
Geraldine Reilly (2795326)
Peter Borg (2795329)
David Piontkowsky (2795320)
Felipe Rogatto (2795323)

May 2016

To the right of zero favors ABC/3TC/DTG (If the risk difference percentage is higher (lower) than...

Hazard ratios (HRs) with their 95% confidence intervals (CIs) of incident knee osteoarthritis between categories of various factors.

Sanna Konstari (6503792)
Laura Sares-Jäske (6503795)
Markku Heliövaara (81299)
Harri Rissanen (4249534)
Paul Knekt (277011)
Jari Arokoski (5576240)
Jouko Sundvall (392546)
Jaro Karppinen (81295)

March 2019

Hazard ratios (HRs) with their 95% confidence intervals (CIs) of incident knee osteoarthritis betwee...

Fig 1 -

Luc Heerkens (16954658)
Laurens A. van Kleef (16954661)
Robert J. de Knegt (11930912)
Trudy Voortman (3497534)
Johanna M. Geleijnse (7246343)

September 2023

Associations in hazard ratios of FLI as continuous exposure in relation to CVD mortality (A) and all...

Risk for treatment discontinuation in treatment-naive patients (Treatment effects showing Hazard Ratios from univariate and multivariate Cox regression models).

Amanda Häggblom (393667)
Stefan Lindbäck (3753223)
Magnus Gisslén (176506)
Leo Flamholc (3753220)
Bo Hejdeman (599663)
Andreas Palmborg (3753214)
Amy Leval (350406)
Eva Herweijer (776415)
Sverrir Valgardsson (3753217)
Veronica Svedhem (2838425)

February 2017

Risk for treatment discontinuation in treatment-naive patients (Treatment effects showing Hazard ...

Unadjusted and adjusted hazard ratios (HR) according to CD4 count at start of ART and at 10 years after start of ART.

Adam Trickey (2950596)
Margaret T. May (627545)
Janne Vehreschild (2950620)
Niels Obel (135891)
Michael John Gill (2950599)
Heidi Crane (2950614)
Christoph Boesecke (779781)
Hasina Samji (486303)
Sophie Grabar (697347)
Charles Cazanave (606308)
Matthias Cavassini (146654)
Leah Shepherd (2950608)
Antonella d’Arminio Monforte (2198545)
Colette Smit (89579)
Michael Saag (170633)
Fiona Lampe (282424)
Vicky Hernando (2950605)
Marta Montero (2950611)
Robert Zangerle (288358)
Amy C. Justice (229955)
Timothy Sterling (2950602)
Jose Miro (2950623)
Suzanne Ingle (2950617)
Jonathan A. C. Sterne (123321)

August 2016

Unadjusted and adjusted hazard ratios (HR) according to CD4 count at start of ART and at 10 years...

Unadjusted and adjusted hazard ratios and 95% CIs for the association between baseline characteristics and discontinuation of TDF from TDF-containing ART regimens in participants in the PEARLS, OCTANE, STRIDE, and REMEMBER clinical trials.

Abstract

Extracted data

Unadjusted and adjusted hazard ratios and 95% CIs for the association between baseline characteristics and discontinuation of TDF from TDF-containing ART regimens in participants in the PEARLS, OCTANE, STRIDE, and REMEMBER clinical trials.

Abstract

Extracted data

Related items

Related items